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The reasons we keep inspecting samples of MS tissue, mainly in post mortem and 
sometimes in biopsy tissue, are manifold.  Despite the availability of numerous disease 
models, the pathology of MS remains unique.  Novel pathological insights (sometimes 
important rediscoveries of observations made many decades ago) include the significant 
degree of axonal damage and loss in acute inflammatory demyelinating lesions, the 
involvement of the grey matter, meningeal inflammation, and the non-lesional (diffuse) 
pathology of the MS brain.  The pathology of disease deterioration in MS is a game of 
numbers: inflammation, the accumulation and severity of lesions, the loss of neurons and 
axons, gliosis – all these features can (some more straightforward than others) be 
quantified.  However, ‘deterioration’ refers to a clinical scenario, and in order to use 
pathological observations for the benefit of people with MS (pwMS) translation into 
clinically applicable indices is required.  The main tool for this purpose remains MRI.  The 
interplay between pathological observation, and hard- and software development in MRI 
has resulted in (i) contrast mechanisms that can now be exploited for pwMS, such as 
susceptibility weighted imaging, (ii) the fine tuning of previously used indices for better 
assessment and monitoring of specific pathological features of MS, including quantitative 
techniques, such as magnetisation transfer, relaxation time measurements, diffusion and 
spectroscopy, and (iii) the current key measure of overall tissue loss and prediction of 
disability – atrophy. 
